MWM
IDXG

Merriman Wealth Management’s Interpace Biosciences, Inc. Common Stock IDXG Stock Holding History

Merriman Wealth Management’s Portfolio IDXG Stock Details IDXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-2,000
Closed -$142 – 205
2019
Q2 		$142 Buy
+2,000
New +$14.6K ﹤0.01% 189
2019
Q1 		– Sell
-1,000
Closed -$9K – 237
2018
Q4 		$9K Buy
+1,000
New +$12K ﹤0.01% 170

Other funds holding IDXG

PCM
Perkins Capital Management Wayzata, Minnesota $133M AUM 127.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
MPI
Mairs & Power Inc St Paul, Minnesota $9.79B AUM 20.6% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Merriman Wealth Management's IDXG Position: Q3 2019 in Review

Merriman Wealth Management sold out of Interpace Biosciences, Inc. Common Stock (IDXG) in Q3 2019, closing a stake of 2,000 shares — an estimated $142 sold.

Merriman Wealth Management first reported a position in IDXG in Q4 2018 and held it in 2 quarters. The position peaked at $9K in Q4 2018. 17 funds tracked by Wall St. Rank hold IDXG as of Q3 2019.

  • Merriman Wealth Management reported no remaining Interpace Biosciences, Inc. Common Stock position as of Q3 2019 after selling out during the quarter.
  • Merriman Wealth Management sold 2,000 Interpace Biosciences, Inc. Common Stock shares in Q3 2019, an estimated $142.
  • Merriman Wealth Management first reported a position in Interpace Biosciences, Inc. Common Stock in Q4 2018 and held it in 2 quarters.
  • Merriman Wealth Management's Interpace Biosciences, Inc. Common Stock position peaked at $9K in Q4 2018.
  • 17 funds tracked by Wall St. Rank held Interpace Biosciences, Inc. Common Stock as of Q3 2019.

Based on Merriman Wealth Management's 13F filing for Q3 2019, filed 18 Oct 2019.